免疫チェックポイント阻害薬の市場規模、シェア、動向分析レポート：タイプ別、用途別、流通チャネル別、地域別、セグメント予測、2024年～2030年

免疫チェックポイント阻害薬市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、免疫チェックポイント阻害薬の世界市場規模は2030年までに1,542億5,000万米ドルに達すると予測され、2024年から2030年までのCAGRは17.9%で成長すると予測されています。

市場成長の原動力は、がんの有病率の増加、免疫チェックポイント阻害薬のFDA承認の増加です。さらに、研究機関や主要事業者による研究開発活動の高まりと相まって、がん免疫療法を推進するための資金が増加していることが、市場成長をさらに後押ししています。

複数のがんの有病率の上昇と適切な治療オプションに対するニーズの高まりは、市場の成長を促進すると予想されます。例えば、国際がん研究機関（IARC）によると、2023年には新たに2,070万人以上のがん患者が発生すると予想されています。また、Breast Cancer Statistics and Resourcesによると、2020年には世界中で約230万人の女性が乳がんと診断されました。さらに、化学療法や放射線療法の副作用に対する医療従事者や患者の意識の高まりが、免疫チェックポイント阻害薬などの代替治療薬の成長に影響を与える主な要因となっています。

がん免疫療法に対する資金提供の増加は、近い将来、同市場に有利な機会をもたらすと予想されます。政府や主要機関は、免疫チェックポイント阻害薬を含むがん免疫療法を発展させるための研究開発活動を奨励することで、がん免疫療法の医療費支出を抑制することを目的とした活動に絶えず取り組んでいます。例えば、2023年7月、がん研究所は免疫療法の技術革新を促進するために約2,800万米ドルの助成金を授与しました。同様に、2021年7月、ランキン政府は免疫チェックポイント阻害薬を含むがん治療を改善するために1,800万米ドルの投資を発表しました。このような取り組みが市場の成長を後押ししています。

しかし、がん治療における免疫チェックポイント阻害薬の高額な関連費用と合併症が大きな課題となっています。がん治療のための免疫チェックポイント阻害薬は、免疫関連の有害事象を引き起こす可能性があります。これらの合併症には、皮膚の問題、大腸炎などの胃腸障害、内分泌機能障害、肺炎、リウマチ症状、神経系や心臓の合併症、腎臓の問題などが含まれます。ICIはがんに大きな効果を示すもの、こうした副作用が予測期間中の市場成長の妨げになると予想されます。

免疫チェックポイント阻害薬市場レポートハイライト

• 製品タイプ別では、研究開発活動の活発化、製品承認の増加、ペムブロリズマブやニボルマブなどの薬剤処方の急増により、PD-1分野が2023年に73.3%の最大売上シェアで市場をリードしました。
• 用途別では、肺がん分野が2023年に25.41%の最大売上シェアで市場を占めました。肺がん患者数の増加がこのセグメントの成長を促す重要な要因です。
• 用途別では、大腸がん分野が予測期間中に最も速いCAGRで成長する見込みです。
• 流通チャネル別では、医薬品調達のアクセス性と利便性の向上により、オンライン薬局分野が予測期間中に最も速いCAGRで成長する見込みです。
• 北米は、がんの有病率の増加、高い購買力平価、質の高いヘルスケアに対する政府の支援、償還の利用可能性などの要因により、2023年の売上高シェア62.81%で市場を独占しました。
• 2023年3月、BioNTech社はOncoC4社と戦略的提携を結び、複数の固形がんを適応症とする新規免疫チェックポイント阻害薬抗CTLA-4モノクローナル抗体候補の共同開発および商業化を開始しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 免疫チェックポイント阻害薬市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場牽引要因分析
  • 市場抑制要因分析
• 免疫チェックポイント阻害薬市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • 価格分析
  • パイプライン分析

第4章 免疫チェックポイント阻害薬市場：タイプ推定・動向分析

• 世界の免疫チェックポイント阻害薬市場：タイプダッシュボード
• 世界の免疫チェックポイント阻害薬市場：タイプ変動分析
• タイプ別、収益
• PD-1
• PD-L1
• CTLA-4
• その他

第5章 免疫チェックポイント阻害薬市場：用途推定・動向分析

• 世界の免疫チェックポイント阻害薬市場：用途ダッシュボード
• 世界の免疫チェックポイント阻害薬市場：用途変動分析
• 用途別、収益
• 肺がん
• 乳がん
• 膀胱がん
• 悪性黒色腫
• 子宮頸がん
• ホジキンリンパ腫
• 大腸がん
• その他

第6章 免疫チェックポイント阻害薬市場：流通チャネルの推定・動向分析

• 世界の免疫チェックポイント阻害薬市場：流通チャネルダッシュボード
• 世界の免疫チェックポイント阻害薬市場：流通チャネル変動分析
• 流通チャネル別、収益
• 病院薬局
• 小売薬局
• オンライン薬局

第7章 免疫チェックポイント阻害薬市場：地域推定・動向分析

• 地域別市場シェア分析、2023年および2030年
• 地域市場ダッシュボード
• 世界地域市場スナップショット
• 市場規模、予測同行分析、2018年から2030年：
• 北米
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • ノルウェー
  • スウェーデン
  • デンマーク
• アジア太平洋地域
  • 日本
  • 中国
  • インド
  • オーストラリア
  • 韓国
  • タイ
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要ディストリビューターおよびチャネルパートナーのリスト
  • 主要顧客
  • 主要企業の市場シェア分析、2023年
  • Sanofi
  • F. Hoffmann-La Roche Ltd.
  • Merck &Co.
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Regeneron Pharmaceuticals Inc.
  • AstraZeneca PLC
  • Shanghai Jhunsi Biosciences Ltd
  • Immutep Ltd
  • BeiGene Ltd
  • GlaxoSmithKline PLC

List of Tables

• Table 1 List of abbreviation
• Table 2 North America immune checkpoint inhibitors market, by region, 2018 - 2030 (USD Million)
• Table 3 North America immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 4 North America immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 5 North America immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 6 U.S. immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 7 U.S. immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 8 U.S. immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 9 Canada immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 10 Canada immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 11 Canada immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 12 Europe immune checkpoint inhibitors market, by region, 2018 - 2030 (USD Million)
• Table 13 Europe immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 14 Europe immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 15 Europe immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 16 Germany immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 17 Germany immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 18 Germany immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 19 U.K. immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 20 U.K. immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 21 U.K. immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 22 France immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 23 France immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 24 France immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 25 Italy immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 26 Italy immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 27 Italy immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 28 Spain immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 29 Spain immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 30 Spain immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 31 Denmark immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 32 Denmark immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 33 Denmark immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 34 Sweden immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 35 Sweden immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 36 Sweden immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 37 Norway immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 38 Norway immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 39 Norway immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 40 Asia Pacific immune checkpoint inhibitors market, by region, 2018 - 2030 (USD Million)
• Table 41 Asia Pacific immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 42 Asia Pacific immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 44 China immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 45 China immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 46 China immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 47 Japan immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 48 Japan immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 49 Japan immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 50 India immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 51 India immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 52 India immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 53 South Korea immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 54 South Korea immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 55 South Korea immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 56 Australia immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 57 Australia immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 58 Australia immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 59 Thailand immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 60 Thailand immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 61 Thailand immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 62 Latin America immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 63 Latin America immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 64 Latin America immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 65 Brazil immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 66 Brazil immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 67 Brazil immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 68 Mexico immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 69 Mexico immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 70 Mexico immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 71 Argentina immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 72 Argentina immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 73 Argentina immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 74 MEA immune checkpoint inhibitors market, by region, 2018 - 2030 (USD Million)
• Table 75 MEA immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 76 MEA immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 77 MEA immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 78 South Africa immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 79 South Africa immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 80 South Africa immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 81 Saudi Arabia immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 82 Saudi Arabia immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 83 Saudi Arabia immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 84 UAE immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 85 UAE immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 86 UAE immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)
• Table 87 Kuwait immune checkpoint inhibitors market, by type, 2018 - 2030 (USD Million)
• Table 88 Kuwait immune checkpoint inhibitors market, by application, 2018 - 2030 (USD Million)
• Table 89 Kuwait immune checkpoint inhibitors market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Primary interviews in APAC
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 QFD modeling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Immune checkpoint inhibitors market: market outlook
• Fig. 10 Immune checkpoint inhibitors competitive insights
• Fig. 11 Parent market outlook
• Fig. 12 Related/ancillary market outlook
• Fig. 13 Penetration and growth prospect mapping
• Fig. 14 Industry value chain analysis
• Fig. 15 Immune checkpoint inhibitors market driver impact
• Fig. 16 Immune checkpoint inhibitors market restraint impact
• Fig. 17 Immune checkpoint inhibitors market strategic initiatives analysis
• Fig. 18 Immune checkpoint inhibitors market: Type movement analysis
• Fig. 19 Immune checkpoint inhibitors market: Type outlook and key takeaways
• Fig. 20 PD-1 market estimates and forecast, 2018 - 2030
• Fig. 21 PD-L1 estimates and forecast, 2018 - 2030
• Fig. 22 CTLA-4 market estimates and forecast, 2018 - 2030
• Fig. 23 Others estimates and forecast, 2018 - 2030
• Fig. 24 Immune checkpoint inhibitors market: Application movement analysis
• Fig. 25 Immune checkpoint inhibitors market: Application outlook and key takeaways
• Fig. 26 Lung cancer market estimates and forecasts, 2018 - 2030
• Fig. 27 Breast cancer market estimates and forecasts,2018 - 2030
• Fig. 28 Bladder cancer market estimates and forecasts,2018 - 2030
• Fig. 29 Melanoma market estimates and forecasts, 2018 - 2030
• Fig. 30 Cervical cancer market estimates and forecasts,2018 - 2030
• Fig. 31 Hodgkin lymphoma market estimates and forecasts,2018 - 2030
• Fig. 32 Colorectal cancer market estimates and forecasts, 2018 - 2030
• Fig. 33 Others market estimates and forecasts,2018 - 2030
• Fig. 34 Immune checkpoint inhibitors market: Distribution channel movement analysis
• Fig. 35 Immune checkpoint inhibitors market: Distribution channel outlook and key takeaways
• Fig. 36 Hospital pharmacies market estimates and forecasts, 2018 - 2030
• Fig. 37 Retail pharmacies market estimates and forecasts,2018 - 2030
• Fig. 38 Online pharmacies market estimates and forecasts, 2018 - 2030
• Fig. 39 Global immune checkpoint inhibitors market: Regional movement analysis
• Fig. 40 Global immune checkpoint inhibitors market: Regional outlook and key takeaways
• Fig. 41 Global immune checkpoint inhibitors market share and leading players
• Fig. 42 North America market share and leading players
• Fig. 43 Europe market share and leading players
• Fig. 44 Asia Pacific market share and leading players
• Fig. 45 Latin America market share and leading players
• Fig. 46 Middle East & Africa market share and leading players
• Fig. 47 North America, by country
• Fig. 48 North America market estimates and forecasts, 2018 - 2030
• Fig. 49 US market estimates and forecasts, 2018 - 2030
• Fig. 50 Canada market estimates and forecasts, 2018 - 2030
• Fig. 51 Europe market estimates and forecasts, 2018 - 2030
• Fig. 52 UK market estimates and forecasts, 2018 - 2030
• Fig. 53 Germany market estimates and forecasts, 2018 - 2030
• Fig. 54 France market estimates and forecasts, 2018 - 2030
• Fig. 55 Italy market estimates and forecasts, 2018 - 2030
• Fig. 56 Spain market estimates and forecasts, 2018 - 2030
• Fig. 57 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 58 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 59 Norway market estimates and forecasts, 2018 - 2030
• Fig. 60 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 61 China market estimates and forecasts, 2018 - 2030
• Fig. 62 Japan market estimates and forecasts, 2018 - 2030
• Fig. 63 India market estimates and forecasts, 2018 - 2030
• Fig. 64 Thailand market estimates and forecasts, 2018 - 2030
• Fig. 65 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 66 Australia market estimates and forecasts, 2018 - 2030
• Fig. 67 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 68 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 69 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 70 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 71 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 72 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 73 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 74 UAE market estimates and forecasts, 2018 - 2030
• Fig. 75 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 76 Market share of key market players - Immune checkpoint inhibitors market

Immune Checkpoint Inhibitors Market Growth & Trends:

The global immune checkpoint inhibitors market size is anticipated to reach USD 154.25 billion by 2030 and is projected to grow at a CAGR of 17.9% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market growth is driven by increasing prevalence of cancer, and growing FDA approvals of immune checkpoint inhibitors. Moreover, increasing funding for advancing cancer immunotherapy coupled with rising R&D activities by research institutes and key operating players are further impelling market growth.

The rise in prevalence of multiple cancers and increase in need for appropriate treatment options are anticipated to drive market growth. For instance, according to the International Agency for Research on Cancer (IARC), over 20.7 million new cancer cases were expected in 2023.In addition, according to the Breast Cancer Statistics and Resources, about 2.3 million women were diagnosed with breast cancer across the globe in 2020. Moreover, increased awareness among healthcare providers and patients about the adverse effects of chemotherapy & radiation therapy is a primary factor influencing the growth of alternative therapeutics, such as immune checkpoint inhibitors.

Growing funding for cancer immunotherapy is anticipated to offer lucrative opportunities for the market in the near future. Government and key organizations engage constantly in activities intended at curbing cancer immunotherapy healthcare expenditure by encouraging R&D activities to advance cancer immunotherapy including immune checkpoint inhibitors. For instance, in July 2023, the Cancer Research Institute awarded about USD 28 million in grants to boost innovations in immunotherapy. Similarly, in July 2021, the Rankin government announced an investment of USD 18 million to improve cancer therapy including immune checkpoint inhibitors. Such initiatives are driving market growth.

However, the high cost associated and complications of immune checkpoint inhibitors in cancer therapy pose a significant challenge. Immune checkpoint inhibitors for cancer treatment can lead to immune-related adverse events. These complications include skin issues, gastrointestinal problems like colitis, endocrine dysfunctions, pulmonary inflammation, rheumatologic symptoms, nervous system and cardiac complications, and renal issues. Although ICIs show significant success against cancer, these side effects are anticipated to hamper market growth during the forecast period.

Immune Checkpoint Inhibitors Market Report Highlights:

• Based on type, the PD-1 segment led the market with the largest revenue share of 73.3% in 2023, owing to growing R&D activities, increasing product approvals and surge in prescription of drugs such as pembrolizumab and nivolumab
• Based on application, the lung cancer segment held the market with the largest revenue share of 25.41% in 2023. Increase in number of lung cancer cases is a significant factor driving growth of this segment
• Based on application, the colorectal cancer segment is expected to grow at the fastest CAGR over forecast period
• Based on the distribution channel, the online pharmacy segment is expected to grow at the fastest CAGR over the forecast period, owing to the increasing accessibility and convenience of drug procurement
• North America dominated the market with the revenue share of 62.81% in 2023, owing to factors such as increasing prevalence of cancer, high purchasing power parity, government support for quality healthcare, and availability of reimbursement
• In March 2023, BioNTech, entered into strategic collaboration with OncoC4 to co-develop and commercialize new immune checkpoint inhibitor anti-CTLA-4 monoclonal antibody candidate for multiple solid tumor indications.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Application
  • 1.2.3. End Use
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in Asia Pacific
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type outlook
  • 2.2.2. Application outlook
  • 2.2.3. End Use outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Immune Checkpoint Inhibitors Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing prevalence of cancer
    • 3.2.1.2. Increasing R&D investments
    • 3.2.1.3. Rise in healthcare spending
    • 3.2.1.4. New product approvals and launches
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. High cost of immune checkpoint inhibitors
• 3.3. Immune Checkpoint Inhibitors Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis
  • 3.3.4. Pipeline Analysis

Chapter 4. Immune Checkpoint Inhibitors Market: Type Estimates & Trend Analysis

• 4.1. Global Immune Checkpoint Inhibitors Market: Type Dashboard
• 4.2. Global Immune Checkpoint Inhibitors Market: Type Movement Analysis
• 4.3. Global Immune Checkpoint Inhibitors Market Estimates and Forecasts, by Type, Revenue (USD Million)
• 4.4. PD-1
  • 4.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.5. PD-L1
  • 4.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.6. CTLA-4
  • 4.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 4.7. Others
  • 4.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Immune Checkpoint Inhibitors Market: Application Estimates & Trend Analysis

• 5.1. Global Immune Checkpoint Inhibitors Market: Application Dashboard
• 5.2. Global Immune Checkpoint Inhibitors Market: Application Movement Analysis
• 5.3. Global Immune Checkpoint Inhibitors Market Estimates and Forecasts, by Application, Revenue (USD Million)
• 5.4. Lung Cancer
  • 5.4.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.5. Breast Cancer
  • 5.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.6. Bladder Cancer
  • 5.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.7. Melanoma
  • 5.7.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.8. Cervical Cancer
  • 5.8.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.9. Hodgkin Lymphoma Cancer
  • 5.9.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.10. Colorectal Cancer
  • 5.10.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 5.11. Others
  • 5.11.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Immune Checkpoint Inhibitors Market: Distribution Channel Estimates & Trend Analysis

• 6.1. Global Immune Checkpoint Inhibitors Market: Distribution Channel Dashboard
• 6.2. Global Immune Checkpoint Inhibitors Market: Distribution Channel Movement Analysis
• 6.3. Global Immune Checkpoint Inhibitors Market Estimates and Forecasts, by Distribution Channel, Revenue (USD Million)
• 6.4. Hospital Pharmacies
  • 6.4.1. Market estimates and forecasts, 2018 to 2030 (USD million)
• 6.5. Retail Pharmacies
  • 6.5.1. Market estimates and forecasts, 2018 to 2030 (USD Million)
• 6.6. Online Pharmacies
  • 6.6.1. Market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Immune Checkpoint Inhibitors Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.5. North America
  • 7.5.1. U.S.
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5.2. Canada
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.6. Europe
  • 7.6.1. UK
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.2. Germany
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.3. France
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework/ reimbursement structure
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.4. Italy
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework/ reimbursement structure
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.5. Spain
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework/ reimbursement structure
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.6. Norway
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework/ reimbursement structure
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.7. Sweden
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework/ reimbursement structure
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6.8. Denmark
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework/ reimbursement structure
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Japan
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.2. China
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.3. India
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.4. Australia
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.5. South Korea
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework/ reimbursement structure
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.7.6. Thailand
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework/ reimbursement structure
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.8. Latin America
  • 7.8.1. Brazil
    • 7.8.1.1. Key country dynamics
    • 7.8.1.2. Regulatory framework/ reimbursement structure
    • 7.8.1.3. Competitive scenario
    • 7.8.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8.2. Mexico
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework/ reimbursement structure
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework/ reimbursement structure
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
• 7.9. MEA
  • 7.9.1. South Africa
    • 7.9.1.1. Key country dynamics
    • 7.9.1.2. Regulatory framework/ reimbursement structure
    • 7.9.1.3. Competitive scenario
    • 7.9.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9.2. Saudi Arabia
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework/ reimbursement structure
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9.3. UAE
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework/ reimbursement structure
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.9.4. Kuwait
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework/ reimbursement structure
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2023
  • 8.3.4. Sanofi
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. F. Hoffmann-La Roche Ltd.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Merck & Co.
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Bristol-Myers Squibb Company
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Eli Lilly and Company
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Regeneron Pharmaceuticals Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. AstraZeneca PLC
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Shanghai Jhunsi Biosciences Ltd
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Immutep Ltd
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. BeiGene Ltd
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. GlaxoSmithKline PLC
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
    • 8.3.14.4. Strategic initiatives